Novartis Gains EU Conditional Approval for Vijoice in Rare PIK3CA-Related Overgrowth Disorder PROS

Novartis faces a defined post-authorisation compliance runway after the European Medicines Agency recommended a conditional marketing authorisation for Vijoice (alpelisib) in PIK3CA-Related Overgrowth Spectrum (PROS), a rare and potentially life-threatening condition affecting both adults and paediatric patients. The conditional designation means the approval is contingent on further confirmatory data, a structural obligation that extends well beyond the regulatory affairs function.

Under EU conditional marketing authorisation rules, Novartis is required to conduct additional studies confirming long-term efficacy and safety across both age cohorts. For QA directors and pharmacovigilance leads, this translates into sustained post-marketing surveillance infrastructure, periodic benefit-risk reporting aligned with ICH E2E guidance, and readiness for EMA review cycles tied to each confirmatory milestone. Any gap in study execution or data submission carries the risk of authorisation suspension.

PROS encompasses a heterogeneous group of disorders driven by somatic activating mutations in the PIK3CA gene, causing segmental tissue overgrowth that can compromise organ function and carry significant morbidity. The rarity of the condition, and the absence of established alternatives, informed the EMA's benefit-risk calculus under its conditional approval pathway, which is designed precisely for settings where unmet medical need is high and complete clinical datasets are not yet available at the time of authorisation.

From a manufacturing and supply standpoint, conditional status introduces a layer of regulatory vigilance that standard approvals do not. Batch release, labelling, and risk management plan (RMP) updates must remain synchronised with evolving post-marketing commitments. Any protocol amendments to confirmatory trials will require regulatory notification, and manufacturing changes during the conditional period will be scrutinised against the approved dossier with heightened EMA attention.

For plant heads overseeing alpelisib production, the practical read is that GMP compliance documentation must be maintained at inspection-ready standard throughout the conditional period, EMA re-assessment intervals are fixed, and a manufacturing deviation that surfaces during a confirmatory study review cycle carries compounded regulatory risk.

The EMA's Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion; the European Commission's formal decision, which converts the CHMP recommendation into a legally binding authorisation across EU member states, is the next procedural step.

Confirmatory study readout timelines, once published in the European Public Assessment Report, will set the measurable compliance checkpoints against which Novartis's post-marketing performance will be evaluated.

Source: Media4Growth via Indian Pharma Post, 25 May 2026.